AD HOC NEWS

Ad Hoc News


2019

13.05.2019

Strafrechtliche massnahmen gegen den ehemaligen vorstand thomas j. svoboda und zwei mutmasslichen mitwissern sind erfolgt

18.04.2019

Elanix Biotechnologies AG: NOMINATION OF THE CHAIRMAN OF THE SUPERVISORY BOARD, THE VICE CHAIRMAN AND MEMBERS OF THE BOARD

14.02.2019

Elanix Biotechnologies AG: Resignation in Supervisory Board

14.02.2019

Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

11.02.2019

Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for fy 2017

07.02.2019

Elanix Biotechnologie AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board


2018

23.11.2018

Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG

12.11.2018

Elanix Biotechnologies AG: Revocation of the appointment of Mr. Tomas J. Svoboda (CEO) as member of the Executive Management Board (Vorstand)

09.11.2018

The Management Board of Elanix Biotechnologies AG will make corrections to its 2017 financial statements due to a fault detection by Deutsche Prüfstelle für Rechnungslegung with regard to the accounting of intangible assets in the 2015 consolidated financial statements.

24.07.2018

Elanix Biotechnologies AG resolves a capital increase of up to 10 percent equaling 2.1 Mio EUR with indirect subscription rights using the authorized capital

28.05.2018

Elanix Biotechnologies AG resolves a capital increase of up to 10 percent with the exclusion of subscription rights using the authorized capital

30.04.2018

Elanix Biotechnologies AG secures up to EUR 2.5 Million SEDA (Standby Equity Distribution Agreement) financing

20.02.2018

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

14.02.2018

Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of 300,019 shares from the current cash capital increase and signs a Term Sheet for financing facility of up to EUR 11 Million


2017

17.10.2017

Agreement in principle reached on the conditions for a non-cash capital increase against a contribution in kind for the progenitor bone cell bank from Inno 4 Cell AG

22.08.2017

Annual General Meeting resolves cash capital increase with preemptive rights at a subscription ratio of 4:1

22.08.2017

Elanix Biotechnologies AG starts due diligence to acquire a fetal progenitor bone cell line within a capital increase by way of contribution in kind

29.06.2017

Elanix Biotechnologies AG: Torsten Cejka, Chairman of the Supervisory Board resigns effective on the date of next General Meeting

13.07.2017

The Management and Supervisory Board will propose to the annual general meeting a capital increase against cash contributions up to 50% granting indirect subscription rights

30.01.2017

Elanix Biotechnologies AG initiates a cash capital increase from authorized capital of up to 1,133,200 new shares with indirect shareholder subscription rights

15.04.2017

Elanix Biotechnologies AG: Restatement gem. IAS 8 im Rahmen des Konzernabschlusses 2016 geplant/Vorläufige, ungeprüfte Konzernzahlen zum Geschäftsjahr 2016 und Ausblick

24.02.2017

Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million

13.01.2017

Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights


2016

20.06.2016

Elanix Biotechnologies AG: Vorstand Armin Schulz abberufen

11.08.2016

Elanix Biotechnologies AG: Kapitalerhöhung vollständig platziert

15.04.2016

Elanix Biotechnologies AG beschließt Kapitalerhöhung

29.07.2016

Elanix Biotechnologies AG beschließt Kapitalerhöhung gegen Bareinlagen aus genehmigtem Kapital

30.09.2016

ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA

15.02.2016

Tomas Svoboda joins Management Board

04.01.2016

Reappointment of Supervisory Board


2015

24.09.2015

Porta Systems AG: Hauptversammlung schafft Voraussetzungen für Neuausrichtung als Biotechnologieunternehmen

09.12.2015

Restructuring to Biotech Company


2014

17.04.2014

Porta Systems AG wird zur ELANIX Biotech AG